Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Top Page
Chemomab Therapeutics
(NASDAQ:CMMB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-10.18% Downside)
Action:UpgradedDate:03/26/26
The score is primarily constrained by weak financial fundamentals (pre-revenue, ongoing losses, and negative free cash flow) and a technically weak price trend below major moving averages. Valuation contributes limited support due to the negative P/E and lack of dividend yield data.
Positive Factors
Regulatory alignment for single Phase 3
Agreement with the FDA on a single Phase 3 registration trial and an event-driven composite endpoint materially reduces regulatory execution risk. A streamlined pathway shortens development timelines, lowers incremental trial complexity and cost, and increases attractiveness to strategic partners over the next 2–6 months and beyond.
Negative Factors
Pre-revenue, persistent losses
Chemomab remains pre-revenue with recurring operating losses and negative free cash flow. Without product sales, profitability depends on successful clinical progression and external funding; persistent losses dilute equity and amplify execution risk if clinical milestones or commercial prospects slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment for single Phase 3
Agreement with the FDA on a single Phase 3 registration trial and an event-driven composite endpoint materially reduces regulatory execution risk. A streamlined pathway shortens development timelines, lowers incremental trial complexity and cost, and increases attractiveness to strategic partners over the next 2–6 months and beyond.
Read all positive factors
Chemomab Therapeutics (CMMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.01M
Dividend YieldN/A
Average Volume (3M)207.96K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth53.19%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-80.60
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$15.00Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Chemomab Therapeutics Business Overview & Revenue Model
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders...
How the Company Makes Money
null...
Chemomab Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -70.56K | -53.25K | -66.83K | -57.77K | -34.02K |
| EBITDA | -9.57M | -13.96M | -25.39M | -28.48M | -12.33M |
| Net Income | -9.07M | -13.95M | -24.22M | -27.65M | -12.48M |
Balance Sheet | |||||
| Total Assets | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M |
| Cash, Cash Equivalents and Short-Term Investments | 10.37M | 14.27M | 19.78M | 39.89M | 61.16M |
| Total Debt | 0.00 | 324.00K | 392.00K | 214.00K | 343.00K |
| Total Liabilities | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M |
| Stockholders Equity | 12.33M | 13.54M | 17.00M | 36.22M | 61.47M |
Cash Flow | |||||
| Free Cash Flow | -11.22M | -15.46M | -23.55M | -20.36M | -12.62M |
| Operating Cash Flow | -11.22M | -15.46M | -23.55M | -20.29M | -12.38M |
| Investing Cash Flow | 5.43M | 2.31M | 15.84M | 19.46M | -45.22M |
| Financing Cash Flow | 7.21M | 9.91M | 3.49M | -804.84K | 61.12M |
Chemomab Therapeutics Technical Analysis
Negative
1.67
Price Trends
1.68
Negative
1.89
Negative
2.70
Negative
Market Momentum
-0.03
Negative
48.66
Neutral
54.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMMB, the sentiment is Negative. The current price of 1.67 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.68, and below the 200-day MA of 2.70, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.66 is Neutral, neither overbought nor oversold. The STOCH value of 54.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMMB.
Chemomab Therapeutics Risk Analysis
Chemomab Therapeutics disclosed 60 risk factors in its most recent earnings report. Chemomab Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chemomab Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $31.73M | -0.82 | -87.18% | ― | ― | 38.42% | |
53 Neutral | $248.08M | -9.09 | -51.83% | ― | ― | 92.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.99M | -0.39 | -119.92% | ― | -22.41% | 78.88% | |
47 Neutral | $73.88M | 0.18 | 1630.23% | ― | ― | 49.57% | |
43 Neutral | $12.01M | -1.16 | -89.92% | ― | ― | 53.19% | |
40 Underperform | $9.73M | -3,346.34 | -526.36% | ― | ― | -2.46% |
* Healthcare Sector Average
CMMB
Chemomab Therapeutics
1.67
-3.05
-64.62%
TENX
Tenax Therapeutics
14.43
8.97
164.19%
QTTB
Q32 Bio
5.05
3.13
163.02%
PASG
Passage Bio
9.89
2.23
29.11%
CALC
CalciMedica
0.62
-1.01
-62.15%
LGVN
Longeveron
1.16
-0.29
-19.72%
Chemomab Therapeutics Corporate Events
Chemomab Therapeutics Sets April 28, 2026 Shareholder Meeting to Vote on Capital Increase and Governance Matters
Mar 20, 2026
Chemomab Therapeutics has called its Annual General Meeting of shareholders for April 28, 2026, in Ramat Gan, Israel, and on March 20, 2026, filed a Form 6-K furnishing the notice, proxy statement and proxy card to investors. The meeting will ask ...
Chemomab Sets Single-Phase 3 Path With FDA After Strong 2025 Nebokitug Data
Mar 19, 2026
On March 19, 2026, Chemomab Therapeutics reported its year-end and fourth quarter 2025 results, highlighting 2025 as a pivotal year marked by positive Phase 2 SPRING trial data for nebokitug in primary sclerosing cholangitis and a successful FDA E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.